Successful treatment of anti-PTX3 positive seronegative rheumatoid arthritis with upadacitinib

Haojie Xu; Bang Su; Rong Li; Lu Wang; Jiaxin Zhou; Lidan Zhao

doi:10.1111/1756-185X.14899

Successful treatment of anti-PTX3 positive seronegative rheumatoid arthritis with upadacitinib

Int J Rheum Dis. 2024 Jan;27(1):e14899. doi: 10.1111/1756-185X.14899. Epub 2023 Sep 13.

Authors

Haojie Xu^{1

2

3}, Bang Su⁴, Rong Li^{1

2

3}, Lu Wang^{1

2

3}, Jiaxin Zhou^{1

2

3}, Lidan Zhao^{1

2

3}

Affiliations

¹ Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical, Sciences/Peking Union Medical College, Beijing, China.
² National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
³ Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
⁴ Department of Hand and Foot Surgery, Bethune First Hospital of Jilin University, Changchun, China.

PMID: 37705400
DOI: 10.1111/1756-185X.14899

Abstract

Seronegative rheumatoid arthritis (SNRA) can be a rapid-progressing and highly disabling disease. Anti-PTX3 autoantibody may be a potential biomarker in SNRA diagnosis. SNRA patients could respond well to upadacitinib.

Keywords: anti-PTX3 positivity; seronegative rheumatoid arthritis; upadacitinib.

Publication types

Case Reports

MeSH terms

Antirheumatic Agents* / therapeutic use
Arthritis, Rheumatoid* / diagnosis
Arthritis, Rheumatoid* / drug therapy
Biomarkers
Heterocyclic Compounds, 3-Ring / therapeutic use
Humans

Substances

upadacitinib
Heterocyclic Compounds, 3-Ring
Biomarkers
Antirheumatic Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding